 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12345678910111213...6970» |
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Review, Journal: HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. (Pubmed Central) - Apr 13, 2024
However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Apr 10, 2024
P3, N=4804, Active, not recruiting, Sponsor: Hoffmann-La Roche
This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments. Trial completion date: Nov 2028 --> Nov 2024
- Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, Perjeta (pertuzumab) / Roche
Real-world costs and site-of-care patterns of fixed-dose subcutaneous vs intravenous formulations of pertuzumab and trastuzumab () - Apr 9, 2024 - Abstract #AMCP2024AMCP_173;
Results were presented using the following 3 groups: PH biosimilar (PHS) when a trastuzumab biosimilar was used, PH brand (PHB) when trastuzumab Brand (Herceptin) was used, and PHSC (Phesgo; subcutaneous)... PHSC is associated with lower total costs of care compared with PHS and PHB, primarily driven by a combination of lower costs of drug, cost of administration, and slight shift of care from outpatient hospital to lower cost site of care.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, FDG PET: Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. (Pubmed Central) - Apr 8, 2024
P2
PHSC is associated with lower total costs of care compared with PHS and PHB, primarily driven by a combination of lower costs of drug, cost of administration, and slight shift of care from outpatient hospital to lower cost site of care. These results highlight the clinical, biological, and metabolic heterogeneity of HER2+?breast cancer, which may facilitate the selection of HER2+?EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tukysa (tucatinib) / Pfizer
Journal, Metastases: Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer. (Pubmed Central) - Apr 7, 2024
Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC)...The median number of prior treatment lines for metastatic disease at TTC treatment initiation was 4 (range, 2-15), including 82 patients (81.2%) with previous trastuzumab and/or pertuzumab and 94 (93.1%) with previous ado-trastuzumab-emtansine) exposure...In this study, TTC therapy was associated with clinically meaningful outcomes in patients with ERBB2-positive MBC after previous trastuzumab-deruxtecan treatment, including those with brain metastases. Prospective data on optimal drug sequencing in this rapidly changing therapeutic landscape are needed.
- | Ogivri (trastuzumab-dkst) / Biocon, Sandoz, Herceptin (trastuzumab) / Roche
Observational data, Journal, Real-world evidence, Patient reported outcomes, Real-world: Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes. (Pubmed Central) - Apr 4, 2024
P, P=N/A
Treatment of patients with HER2-positive BC with the trastuzumab biosimilar Ogivri resulted in equivalent symptoms, adverse events, and well-being as found for patients treated with Herceptin as determined by ePRO data. Hence, integration of an ePRO system into research and clinical practice can provide reliable information when investigating the real-world tolerability and outcomes of similar therapeutic compounds.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Soltamox (tamoxifen citrate) / Jazz, Perjeta (pertuzumab) / Roche
New P2 trial, Surgery: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov) - Apr 4, 2024
P2, N=74, Not yet recruiting, Sponsor: University of Chicago
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. (Pubmed Central) - Apr 3, 2024
HP was active in a selection of HER2-amplified tumors (non-breast/gastroesophageal) but did not meet the predefined efficacy benchmark. Additional strategies targeting HER2 and potential resistance pathways are warranted, especially in rare tumors.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Real-world evidence, Real-world: Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study. (Pubmed Central) - Mar 28, 2024
Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.
- || inavolisib (GDC-0077) / Roche
Enrollment closed, Combination therapy, Metastases: GO39374: To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (clinicaltrials.gov) - Mar 27, 2024
P1, N=256, Active, not recruiting, Sponsor: Genentech, Inc.
Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence. Recruiting --> Active, not recruiting
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Clinical data, Journal, Real-world evidence, Real-world, Metastases: A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice. (Pubmed Central) - Mar 26, 2024
Recruiting --> Active, not recruiting This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 26, 2024
P3, N=315, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression. Trial completion date: Dec 2023 --> Dec 2024
- | imlunestrant (LY3484356) / Eli Lilly
Phase classification, Combination therapy, Monotherapy, Metastases: EMBER: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (clinicaltrials.gov) - Mar 26, 2024
P1, N=500, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2023 --> Dec 2024 Phase classification: P1a/1b --> P1
- | Verzenio (abemaciclib) / Eli Lilly
Phase classification, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Mar 25, 2024
P1, N=198, Active, not recruiting, Sponsor: Eli Lilly and Company
Phase classification: P1a/1b --> P1 Phase classification: P1b --> P1
- | Trial completion date, Trial primary completion date, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Mar 21, 2024
P3, N=400, Recruiting, Sponsor: Massachusetts General Hospital
Phase classification: P1b --> P1 Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2026
- | Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: FINEST: A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC (clinicaltrials.gov) - Mar 21, 2024
P1/2, N=20, Recruiting, Sponsor: Fudan University
Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2026 Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Prognostic role of tumor-infiltrating lymphocytes (TILs) in first-line HER2-positive (HER2+) metastatic breast cancer (BC): a real-world study (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_455;
Based on our analysis, it seems that TILs expression does not play a prognostic role in first-line treated HER2+ BC. However, confirming the correlation with BMs at diagnosis would necessitate a larger case study.
- Trastuzumab biosimilar (TB) in combination with pertuzumab (P) and chemotherapy (CT) in Her2 positive, metastatic breast cancer (MBC) : efficacy and safety. (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_454;
However, confirming the correlation with BMs at diagnosis would necessitate a larger case study. TB was TRAZIMERA
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical features predictive of never-progressive disease to first-line anti-HER2 therapy: real-world data from the ESME national cohort (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_453;
P
Negative hormone receptor status was the main driver of this long-term control. This may support de-escalation strategies in HER2+ patients with long-standing response to therapy.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Real-world treatment patterns in patients with HER2+ unresectable (u) or metastatic (m) breast cancer (BC): HER2 Real study final analysis in Asia-Pacific (APAC) and Brazil (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_452;
P=N/A
The unexpected short PFS and OS outcomes indicate substandard treatment sequencing practices. Poor outcomes and high attrition rates in later lines highlight the need for better treatment alternatives in earlier lines of therapy.
- Perjeta (pertuzumab) / Roche
Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: a SONABRE study (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_451;
In 80% of the patients achieving CR, pertuzumab was stopped early. Patients reaching CR have a better prognosis than those not reaching CR.
- Perjeta (pertuzumab) / Roche
The implementation of first-line pertuzumab and the impact on overall survival in patients with de Novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: a population-based cohort study (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_450;
This advancement was observed in all subgroups except for patients with CNS metastases. The implementation of pertuzumab was slow and deserves attention.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with HER2 positive advanced breast cancer: a multicentric Portuguese study (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_444;
The majority, 77, 2%, had received pertuzumab and 91, 7% T-DM1 previously. In this analysis we found similarities between clinical trial efficacy and real-world effectiveness as well as safety, tolerability and adverse events in the Portuguese population treated with T-DXd after at least 2 previous lines for HER2+ ABC.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Exploratory Pooled Safety Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients With HER2+ or HER2-low Unresectable and/or Metastatic Breast Cancer (mBC) in DESTINY-Breast Trials (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_435;
P2, P3
In this analysis we found similarities between clinical trial efficacy and real-world effectiveness as well as safety, tolerability and adverse events in the Portuguese population treated with T-DXd after at least 2 previous lines for HER2+ ABC. DB-03 compared T-DXd to T-DM1 after trastuzumab (
- Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_382;
P3
Funding: F. Hoffmann-La Roche Ltd. Although there was no increase in pCR rates, 3-yr DFS/EFS rates were numerically improved with A in the ITT population, including in pts with PD-L1
- Nerlynx (neratinib) / Puma
A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer in China: NER-Tree study (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_373;
P
Background: Neratinib, an oral irreversible pan-HER tyrosine kinase inhibitor, was approved in 2020 in China based on the ExteNET trial, which is no longer reflective of the current treatment landscape of HER2+ early breast cancer (EBC) in China, with increasing clinical uses of neoadjuvant treatment and recently approved adjuvant anti-HER2 therapies including pertuzumab and trastuzumab emtansine. The results from the NER-Tree study describe the use of the extended adjuvant neratinib in patients with HER2+ EBC that received more recent anti-HER2 therapies including pertuzumab in combination with trastuzumab in China.
- Nerlynx (neratinib) / Puma
Interim analysis of 300 patients with HER2+/HR+ early breast cancer enrolled in the multi-national, prospective, observational ELEANOR NIS treated with extended adjuvant neratinib in clinical routine (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_371;
P=N/A
This preplanned interim analysis provides additional data for neratinib use in routine clinical practice without any new safety signals. Funding by Pierre Fabre Pharma.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Longitudinal Evaluation of PAM50 Molecular Subtypes in Patients Receiving Neoadjuvant HER2-targeted Therapy in the PREDIX HER2 Trial (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_284;
P2/3
Subtypes exhibit significant intratumoral and temporal heterogeneity. Ongoing analyses investigate the prognostic implications of subtype switch.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive (HER2+) Breast Cancer (BC): Implications for Treatment Stratification (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_274;
The HER2DX ERBB2 mRNA score shows a significant association with improved survival in metastatic HER2+ BC patients treated initially with THP. Additional validation of the HER2DX ERBB2 score and integration of prognostic clinical factors might refine and optimize treatment strategies in this clinical setting.
- Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
Updated findings from the first prospective HER2DX clinical decision impact study on early-stage HER2-positive (HER2+) breast cancer (BC) (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_273;
In pts who de-escalated the antiHER2, 23/29 received less antiHER2 (i.e. avoidance of pertuzumab or neratinib) and 6/29 shortened the duration of trastuzumab. In this first prospective study, HER2DX impacted clinical care in early-stage HER2+ BC and improved the level of confidence of physicians.
- |||| Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: ProHer: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (clinicaltrials.gov) - Mar 18, 2024
P3, N=347, Active, not recruiting, Sponsor: Hoffmann-La Roche
In this first prospective study, HER2DX impacted clinical care in early-stage HER2+ BC and improved the level of confidence of physicians. Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 15, 2024
P2, N=63, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Mar 2025 Trial completion date: Dec 2023 --> Dec 2024
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date: Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 15, 2024
P2, N=120, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Nov 2023
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Perjeta (pertuzumab) / Roche
PHASE II TRIAL OF RIFAXIMIN IN PATIENTS WITH EARLY-STAGE HER2 POSITIVE BREAST CANCER WITH GASTROINTESTINAL TOXICITIES RELATED TO PERTUZUMAB-BASED THERAPY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5089;
A greater abundance of Lawsinobacter asaccharolyticus was observed in patients who developed PIGT after 1 cycle of chemotherapy. Further studies are warranted to evaluate the mechanism of symptom improvement with rifaximin and the microbiome in patients that develop PIGT.
- ipatasertib (RG7440) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC) (Munich Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_224;
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer. (Pubmed Central) - Mar 12, 2024
P2
This four-drug neoadjuvant regimen shows promising pathological response with an acceptable safety profile in patients with TPBC. A randomized controlled trial (NCT05638594) of this regimen is being conducted.
- | Enrollment open, Metastases: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 12, 2024
P2, N=25, Recruiting, Sponsor: Mayo Clinic
A randomized controlled trial (NCT05638594) of this regimen is being conducted. Not yet recruiting --> Recruiting
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: ARIADNE: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 12, 2024
P2, N=370, Recruiting, Sponsor: Karolinska University Hospital
Not yet recruiting --> Recruiting Trial completion date: Dec 2031 --> Apr 2032 | Trial primary completion date: Jun 2026 --> Apr 2027
- | Herceptin (trastuzumab) / Roche, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Perjeta (pertuzumab) / Roche
Journal: Timing of Administration of Pegfilgrastim and Prophylaxis for Febrile Neutropenia for Patients with Early Breast Cancer Receiving Chemotherapy (Pubmed Central) - Mar 11, 2024
Regarding neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer, taxanes and trastuzumab with the addition of pertuzumab have shown higher pathological complete response rates and elevated incidences of FN...The RDI of all regimens was 99.7%. Although there were some differences in chemotherapy regimens, an earlier timing of PEG prophylaxis(especially 24-48 hours from chemotherapy completion)has been shown to reduce the incidence of FN and increase the RDI.
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical guideline, Journal: Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. (Pubmed Central) - Mar 11, 2024
Mutational and mismatch repair and BRAF testing are also strongly recommended for screening for Lynch syndrome. Circulating tumor DNA-based minimal residual disease (MRD) testing is strongly recommended for estimating the risk of recurrence based on clinical evidence, although MRD testing was not approved in Japan at the time of the publication of this guideline.
- | Balversa (erdafitinib) / J&J, Perjeta (pertuzumab) / Roche
Journal, Stroma: Adipose Stromal Cell-Derived Cancer-Associated Fibroblasts Suppress FGFR Inhibitor Efficacy. (Pubmed Central) - Mar 8, 2024
In this issue of Cancer Research, Hosni and colleagues discover a paracrine mechanism mediated by adipocyte precursor cells through which urothelial carcinomas become resistant to erdafitinib, a recently approved therapy inhibiting fibroblast growth factor receptors (FGFR)...The NRG1-mediated FGFR inhibitor resistance was amenable to intervention with pertuzumab, an antibody blocking the NRG1/HER3 axis...Because fibroblasts with the ASC/FAP signature are enriched in various carcinomas, it is possible that the paracrine signaling conferred by NRG1 is a pan-cancer mechanism of FGFR inhibitor resistance and tumor aggressiveness. See related article by Hosni et al., p. 725.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
P2 data, Journal: Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study. (Pubmed Central) - Mar 8, 2024
This dual HER2-blockade with sequential polychemotherapy showed promising activity with rapid tumor regression in HER2-positive BC. Importantly, this regimen showed an acceptable safety profile, especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
The Economic Burden of HER2+ Breast Cancer and the Epidemiological & Economic Impact of Targeted Therapies in the Dominican Republic () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_273;
Also, a population estimation model was performed to determine the impact of targeted HER2+ therapies in BC avoided relapses, prevented metastases, life years (LYs) gained, quality-adjusted life years (QALYs), and metastatic BC cost reduction, comparing a base scenario (chemotherapy alone) vs actual scenario (Chemotherapy & Trastuzumab) vs ideal one (Chemotherapy, Trastuzumab, Pertuzumab & Trastuzumab+Emtansine). The treatment of HER2+ BC in DR is more expensive in the metastatic stages than in neo-adyuvance or adyuvance stages, the use of targeted therapies helps to improve patient
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy: Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxel (EUDRACT) - Mar 7, 2024
P2, N=45, Completed, Sponsor: IFCT
- p38-mediated EZH2 phosphorylation at T367 regulates HER2 pathway in triple negative breast cancer (Section 14) - Mar 5, 2024 - Abstract #AACR2024AACR_9643;
We demonstrate that T367 phosphorylation mediates the effect of EZH2 on HER2 signaling in TNBC. Our data support a role for pEZH2-T367 in maintaining the HER2-negative phenotype in and suggest that blocking this phosphorylation event may render TNBC tumors amenable to anti-HER2 treatment strategies.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
The value of routine trastuzumab-related cardiac toxicity monitoring in gastrointestinal cancers (Section 39) - Mar 5, 2024 - Abstract #AACR2024AACR_7867;
The incidence of clinically significant LVEF drop appears low in patients with advanced GI cancers as post-treatment LVEF recovery to baseline was observed at the population level. The value of using TTE to monitor TRCT in these patients with short OS should be further assessed in the perspective of cost effectiveness.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Next-generation sequencing based detection of HER2 copy number predicts pathological response to neoadjuvant therapy in HER2 positive breast cancer (Section 44) - Mar 5, 2024 - Abstract #AACR2024AACR_7696;
The discordance between IHC/FISH and NGS based detection of HER2 amplification may reflect HER2 heterogeneity. HER2 heterogeneity promotes resistance to anti-HER2 therapy.
- Pozenveo (poziotinib) / Assertio, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
HER2 TKIs enhance the anti-tumor activity of HER2-targeting CAR-T and CAR-NK cells against NSCLC (Section 2) - Mar 5, 2024 - Abstract #AACR2024AACR_6967;
Current HER2-targeting approaches, including antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan, have shown promising response rates...We engineered a series of HER2 CAR constructs utilizing scFvs derived from trastuzumab, pertuzumab, and FRP5, recognizing distinct domains of HER2...Using a HER2 YVMA duplication patient-derived xenograft (PDX) NSCLC model, we observed that the in vivo combination of poziotinib with HER2 CAR-NK cells exhibited superior anti-tumor activity as compared to poziotinib treatment alone. In conclusion, HER2 CAR-T and CAR-NK cells effectively target HER2-mutant and HER2-positive NSCLC, and their combination with HER2 TKIs enhances vulnerability to HER2-targeting strategies.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_6409;
P2
In RD, high expression of immune and luminal genes was associated with a reduced risk, while high expression of proliferation genes was associated with a higher risk. Molecular changes after anti-HER2 therapy were mainly observed in RD of pts that did not relapse.
- Herceptin (trastuzumab) / Roche, Imfinzi (durvalumab) / AstraZeneca, Perjeta (pertuzumab) / Roche
Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial (Hall GH - Ground Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_6026;
Molecular changes after anti-HER2 therapy were mainly observed in RD of pts that did not relapse. Abstract is embargoed at this time.